A recently published meta‐analysis, led by a Chinese group, compared the OS differences between anti‐PD1 and anti‐PD‐L1 across different cancer types in 19 randomized clinical trials involving 11 379 patients, regardless of the number of previous treatments.24 Here, PDCD1 is linked to cancer.